drugset / Trial / NCT05565105

CD34+ Transplants for Leukemia and Lymphoma

NCT05565105

Phase 2 Not yet recruiting 100 enrolled Guenther Koehne
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in less complications for patients undergoing transplant for treatment of a blood malignancy (cancer) or blood disorder.

Timeline

Start
2026-06
Primary completion
2033-06
Completion
2033-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule 0.8 mg/kg Intravenous
Subject Cyclophosphamide Other / unclassified 60 mg/kg Intravenous
Subject Fludarabine Small molecule 25 mg/m2 Intravenous
Subject Melphalan Small molecule 70 mg/m2 Intravenous
Subject Thiotepa Other / unclassified 5 mg/kg Intravenous